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Abstract
Purpose of Review The purpose of this review is to summarize the recently published evidence concerning vertebral fracture risk
in individuals with diabetes mellitus.
Recent Findings Vertebral fracture risk is increased in individuals with T2DM. The presence of vertebral fractures in T2DM is
associated with increased non-vertebral fracture risk and mortality. TBS could be helpful to estimate vertebral fracture risk in
individuals with T2DM. An increased amount of bone marrow fat has been implicated in bone fragility in T2DM. Results from
two recent studies show that both teriparatide and denosumab are effective in reducing vertebral fracture risk also in individuals
with T2DM.
Summary Individuals with T2DM could benefit from systematic screening in the clinic for presence of vertebral fractures.
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Introduction
Osteoporosis and diabetes mellitus are diseases with a high
prevalence and both substantially contribute to the disabil-
ity burden worldwide [1, 2]. Diabetes mellitus is currently
the fourth leading cause of disability worldwide, and in
2016, diabetes mellitus was the fifteenth leading cause of
early death, forecasted to be seventh by 2040 [2].
Similarly, osteoporotic fractures are common, with an es-
timated nine million osteoporotic fractures in the year 2000
[3, 4]. Vertebral fractures, the most common type of oste-
oporotic fractures, are associated with an increased risk of
mortality and non-vertebral fractures [5–7]. Despite the
morbidity and mortality risk associated with occurrence
of vertebral fractures, they remain underdiagnosed [8].
Type 1 diabetes mellitus (T1DM) and type 2 diabetes
mellitus (T2DM), the two most common types of diabetes
mellitus, have convincingly been shown to be associated
with non-vertebral fracture risk in multiple large prospec-
tive studies and meta-analyses [9–13]. However, the evi-
dence concerning vertebral fracture risk in individuals with
diabetes mellitus, especially T2DM, has been less conclu-
sive, providing results ranging from lower to no associa-
tion, and to increased risk [14–19]. There are biological
differences between vertebral fractures and non-vertebral
fractures; these differences originate mainly from different
bone material, biomechanical and functional properties of
the trabecular and cortical bone. Vertebrae are composed
predominantly of trabecular bone surrounded by a thin lay-
er of cortical bone, in contrast to long bones where this
layer is much thicker and the trabecular compartment is
less prominent. Furthermore, trabecular bone is substan-
tially more metabolically active and holds distinct biome-
chanical properties from cortical bone. Individuals with
T1DM have decreased BMD, whereas individuals with
T2DM have increased BMD [20]. Traditional diagnostic
tools that incorporate BMD in fracture risk prediction tend
to underestimate fracture risk in individuals with T2DM
[21•]. Not only changes in bone mass but also changes in
bone micro architecture can cause bone fragility.
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The purpose of this review is to summarize the recently
published evidence concerning vertebral fracture risk among
individuals with diabetes mellitus. To decrease subjectivity
and the chance of missing the inclusion of studies, we per-
formed a sensitive systematic search of the last 5 years of
literature in PubMed with search terms as follows: ((“Spinal
Fractures”[Mesh]) AND (“Diabetes mellitus”[Mesh])) OR
((Diabet* [tiab]) AND (vertebr* [tiab]) AND (fract* [tiab])).
The search resulted in 206 articles which were grouped into
articles that analysed vertebral fracture risk in individuals with
T1DM (n = 0), articles that analysed vertebral fracture risk in
individuals with T2DM (n = 9), articles that concerned non-
vertebral fracture risk and diabetes mellitus and possible path-
ophysiologic links between diabetes mellitus and fracture risk
(n = 71) and studies that did not concern fracture risk in dia-
betes mellitus (n = 125). The literature was independently
reviewed by FK and SG. The literature search showed no
studies examining the risk of vertebral fractures in individuals
with T1DM in the past 5 years; therefore, we re-did the search
without the time constraint for T1DM. Interestingly, we could
identify only two studies who had estimated vertebral fracture
risk in individuals with T1DM. Therefore, this review is fo-
cused on recent findings concerning vertebral fracture risk in
T2DM, and we have provided a short summary for risk of
vertebral fractures in T1DM.
Epidemiology of Vertebral Fractures in T1DM
We could identify only two older studies that have studied the
risk of vertebral fractures among individuals with T1DM [10,
22]. A sex- and age-matched case-control study by
Vestergaard et al. in a total of 498,617 Danish individuals
from the general population found increased odds of vertebral
fractures in individuals with T1DM compare to those without
T1DM (OR = 2.48, 95% CI 1.33–4.62) [10]. Similarly, in a
cross-sectional case-control study with significantly less par-
ticipants (n = 164), Zhukouskaya et al. also reported increased
odds of vertebral fractures among individuals with T1DM
(OR = 4.20, 95% CI 1.40–12.70) [22].
Epidemiology of Vertebral Fractures in T2DM
The relationship between T2DM and vertebral fractures has
been studied more extensively compared to T1DM; never-
theless, until recently the research had been inconclusive
with meta-analyses characterized by high unexplained het-
erogeneity [14–19]. In our recent study, a meta-analysis of
unpublished data from cohort studies and previously pub-
lished studies, we performed two meta-analyses: one with
both previously published and unpublished studies that had
examined the relationship between T2DM and prevalent
vertebral fractures (cross-sectional study design) and one
with studies where the association between T2DM and
incident vertebral fractures (either prospective or retrospec-
tive study design) was examined. In a sample of 37,292
individuals, those with T2DM had lower risk of prevalent
vertebral fractures (OR 0.84 [95% CI 0.74–0.95]) without
evidence of heterogeneity across studies. In a sample of
738,018 individuals, those with T2DM were at increased
risk of incident vertebral fractures (OR 1.35 [95% CI 1.27–
1.44]) with no evidence of heterogeneity across studies
[6••] (Fig. 1). This difference in direction of effect seems
to be explained by the observation that individuals with
both T2DM and vertebral fractures have the highest mor-
tality, and thus, prevalence studies for vertebral fractures in
T2DM are impacted by survivorship selection bias.
Risk Factors for Vertebral Fracture Risk
in T2DM
Decreased BMD is strongly correlated with increased risk of
vertebral fractures; however, in individuals with T2DM,
BMD is on average higher than individuals without T2DM,
suggesting that in T2DM, BMD underestimates the risk of
fracture [20, 21•]. Trabecular bone score (TBS), a marker of
deteriorated trabecular bone quality in patients with T2DM,
has been postulated to be helpful in fracture risk assessment in
patients with diabetes mellitus [23–25, 26•]. In our study, we
reported that individuals with T2DM had higher BMD at the
femoral neck and lumbar spine but lower TBS, compared to
individuals without T2DM, independent of age, sex, medica-
tion use and BMI [6••]. Yamamoto et al. reported that preva-
lent vertebral fractures in individuals with T2DM were asso-
ciated more strongly with TBS than BMD and suggested that
an integrated assessment of bone strength by both BMD and
TBS would help diagnose diabetic osteoporosis [27]. Choi
et al. found indirect evidence that TBS and TBS-adjusted
FRAX could be supplementary tools to predict osteoporotic
fractures in T2DM, in a retrospective cross-sectional study of
prevalent vertebral fractures in 169 Korean postmenopausal
women [28]. Prediction studies on incident vertebral fractures
are desirable. In the study by Zhukouskaya et al., TBS was
found not to differ between individuals with or without T2DM
and that a combination of TBS below 1.130 and BMDT-score
below − 1.0 identified people with T2DM at high risk of ver-
tebral fractures best [29]. These results need to be interpreted
with caution, not only because the sample size is too small to
draw solid conclusions but also because the thresholds used in
the study are based on absolute values and will always be
specific to the population studied and type of DXA used (as
it is the case for TBS in this study) [29]. Similarly, results from
the study by Chen et al. should be interpreted with caution, as
they used cut-off values for TBS that are not derived from
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their study population. They reported that low bone mass and
deteriorated TBS were noted in approximately two-thirds of
women with T2DM and were also associated with vertebral
fractures [30]. We could not find any published article esti-
mating standardized clinical threshold values for TBS neither
in individuals without T2DM nor in individuals with T2DM,
and therefore, further research to define these thresholds is
needed. BMI is a risk factor for vertebral fractures; however,
the relationship is complex, with increased BMI correlated
with increased bone mass but decreased bone quality [31].
Furthermore, studies estimating the association between
BMI and vertebral fractures in individuals with T2DM are
lacking. A study by Kanazawa et al. found that individuals
with T2DM falling in the lowest and highest quartiles of BMI
had increased risk of vertebral fractures compared to individ-
uals in the middle quartile [32]. In our recent study, we found
that T2DM was associated with increased vertebral fracture
risk, only in the underweight category (BMI < 18.5 kg/m2)
and with decreased risk of vertebral fractures in the obese
category (BMI > 30 kg/m2) [6••]. Decreased muscle mass
and mobility as well as increased frailty have been reported
in individuals with T2DM compared to controls [33, 34].
Results from the CaMos cohort suggest that the increased
frailty in individuals with T2DM could increase the risk of
fragility fractures [34]. In the STRAMBO study, Schulz
et al. found that in older men, moderate and severe vertebral
fractures as well as T2DM were independently associated
prospectively with lower grip strength, poor physical function,
and higher risk of multiple falls [35]. In a small cross-sectional
study among Japanese patients with T2DM, falling was cor-
related with vertebral fractures [36]. Vertebral fractures, even
though they are often asymptomatic and go undetected, are
strongly associated with increased incidence of any type of
fracture [37]. In our recent study, we also examined whether
the presence of vertebral fractures in individuals with T2DM
predicts future non-vertebral fractures and whether the asso-
ciation differs by BMD levels [6••]. We found that compared
to people without T2DM or vertebral fractures, those who had
both T2DM and vertebral fractures had 2.5 times increased
hazard ratio to acquire a non-vertebral fracture and a twofold
increased hazard when compared to individuals with T2DM
alone; the estimated increased risk did not vary when the anal-
ysis was stratified by clinical categories of BMD (i.e., normal,
osteopenia and osteoporosis), suggesting that presence of ver-
tebral fractures in individuals with T2DM captures an aspect
of bone fragility different from that of BMD.
Pathophysiology of Non-vertebral
and Vertebral Fracture Risk in T2DM
A systematic review and meta-analysis conducted by Hygum
et al. found that both bone formation and bone resorption
markers are decreased in patients with T2DM, suggesting that
low bone turnover might contribute to increased bone fragility
in patients with T2DM [38]. In fact, growing evidence has
accumulated to postulate that fracture risk in T2DM is a com-
plication of inadequate glucose control [13, 39]. Several
Fig. 1 Forest plot of the meta-analysis across studies showing increased risk of incident vertebral fractures in individuals with T2DM. Figure adapted
with permission [6]
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investigations have been performed to elucidate the molecular
and biomechanical mechanisms underlying bone fragility in
individuals with T2DM and have been described in detail
elsewhere [40]. Levels of advanced glycation end products
(AGEs) have been found to be increased in T2DM and might
contribute to increased bone fragility through impaired en-
zymatic cross-linking and/or an increase in non-enzymatic
cross-links in bone collagen [41]. In a recent study embed-
ded in the Rotterdam Study, skin autofluorescence (SAF), a
non-invasive biomarker of AGEs, was associated positively
with prevalent vertebral fractures [42]. In cortical bone,
compromised bone remodelling likely leads to accumula-
tion of micro cracks, resulting in increased non-vertebral
fracture risk [38–40]. While the processes affecting cortical
bone are starting to be elucidated, evidence regarding the
impact of low bone turnover on vertebral fracture risk is
lacking. The thin cortices of vertebra and the integrity of
the endplate have been shown to be critical for the assess-
ment of vertebral fracture risk but much less is known about
its underlying aetiology [43]. Most of the biomechanical
support of vertebral bodies is believed to arise from the
trabecular bone. This is in line with the finding that the
TBS assessment does pick-up a biomechanical component
not readily assessed by BMD. One of the potential factors
that had been recently linked to decreased bone quality in
individuals with T2DM is increased bone marrow fat. Free
fatty acids released by adipocytes in bone marrow contrib-
ute in inhibiting osteoblast proliferation and function and
inducing osteoblast apoptosis [44]. Elevated HOMA-IR
was linked to higher marrow fat fraction in postmenopausal
women with newly diagnosed T2DM independent of body
composition [45]. Another study reported no association
between bone marrow adipose tissue and bone density/
strength nor with incident fractures. However, they report-
ed that greater bone marrow fat was associated prospective-
ly with greater loss of trabecular bone at the spine and
femoral neck, and greater loss of spine compressive
strength, in older women [46]. The study by Sheu et al.
found significant inverse correlations between bone mar-
row fat estimated with MRI and BMD (− 0.30 for femoral
neck and − 0.39 for total hip) among men with diabetes but
not among those without diabetes [47]. None of the studies
to date have examined whether bone marrow fat is associ-
ated with vertebral fracture risk.
Vertebral Fractures in T2DM and Mortality
In the study by Koromani et al., sensitivity analyses showed
that individuals with T2DM that were obese (BMI > 30.0 kg/
m2) or were 74 years or older had the lowest prevalence of
vertebral fractures [6••]. Subsequently, it was shown that in-
dividuals with both T2DM and vertebral fractures had
increased mortality compared to individuals with vertebral
fractures alone, or T2DM alone. Obese men with T2DM with
vertebral fractures had a strikingly high mortality hazard ratio
compared to obese men with vertebral fractures alone (HR =
3.10, 95% CI 1.25–7.57) and compared to obese men with
T2DM alone (HR = 2.54, 95% CI 1.17–5.51) [6••] (Fig. 2).
Similarly, in another study comprising 498,318 individuals
whose information was extracted form GP databases in
Spain, post-vertebral fracture mortality in individuals with
T2DM was increased compared to individuals without
T2DM (HR = 1.20, 95% CI 1.06–1.35) [48]. Also in a
Japanese study of 411 T2DM patients, in those with grade
3 vertebral fractures, the mortality hazard rate was more
than seven times the hazard rate of those without vertebral
fractures (i.e. < grade 1) [49]. Presence of vertebral frac-
tures in individuals with T2DM seems to be also a marker
of increased frailty; yet more research is needed to identify
causes of excess risk of mortality and on the effectiveness
of measures to reduce post-fracture morbidity and mortality
in individuals with T2DM.
Anti-diabetes Medication and Vertebral
Fracture Risk
The effect of anti-diabetes medication on any type of
fracture risk is not established and shows a trend towards
no statist ical ly signif icant effect . In a nutshell ,
thiazolidinedione (TZD) and insulin have been implicated
with increased fracture risk [50]. No significant effect on
any type of fracture risk was found for metformin, sulfo-
nylureas or DPP-4 inhibitors. Data concerning SGLT2
inhibitors are inconsistent showing increased or no effect
on fracture risk, and currently there is insufficient data
concerning GLP-1 receptor agonists’ effect on fracture
risk [50]. Different types of anti-diabetes treatment may
be associated with differences in risk of vertebral fractures
(Fig. 1). In a nationwide study in Korea, 207,558 individ-
uals on anti-diabetes medication were analysed to estimate
whether the type of anti-diabetes treatment was associated
with vertebral fracture risk. The authors reported that as
compared to non-users, metformin + DPP4-inhibitor com-
bination group had a trend towards a reduced vertebral
fracture risk (HR = 0.73, P = 0.013) and showed a trend
towards lower non-vertebral fracture risk compared to
metformin + sulfonylurea group. From this perspective,
they recommended clinicians to take these results of
DPP4-inhibitors into consideration when prescribing dia-
betes medication, especially in elderly patients or those at
high risk or fracture [51]. In contrast, another study re-
ported that increased serum levels of DPP-4 in individuals
with T2DM were associated with increased odds of ver-
tebral fractures, but not with BMD [52]. Furthermore, Lin
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et al. reported that postmenopausal women with newly
diagnosed T2DM have a higher marrow fat content com-
pared to women without T2DM and that metformin treat-
ment reduced marrow adiposity in T2DM [53]. A study in
rats by Mai et al. suggests that metformin reduces
RANKL, stimulates OPG expression in osteoblasts, in-
hibits osteoclast differentiation and prevents bone loss
[54]. In a meta-analysis aiming to estimate the association
between insulin use and risk of fracture, the authors found
a trend towards increased risk of vertebral fractures
among T2DM patients using insulin, compared to those
using oral anti-diabetic treatment (OR 1.28, 95% CI,
0.90–1.81) [55]. Interestingly, in a study utilizing data
from healthcare databases of the Italian region of
Lombardy, the authors found that patients with T2DM
who switched from oral medication to insulin were at
increased risk of vertebral fractures (HR = 1.8, 95% 1.5–
2.3) mainly in the period immediately after the start of
insulin therapy. The observed association may result from
higher hypoglycaemia; nonetheless, confounding by indi-
cation might play a role, because those individuals that
have a necessity to switch to insulin might be those with
more severe diabetes [56]. No vertebral fracture data are
yet available for glucagon-like peptide-1 (GLP-1) receptor
agonists, where bone turnover markers and BMD seem
preserved in spite of weight loss. [57]
Osteoporosis Medication and Vertebral
Fracture Risk in Individuals with T2DM
Conversely, it is relevant to know if patients with diabetes-
related bone disease benefit similarly of anti-osteoporotic
medication as non-diabetic individuals with osteoporosis.
Evidence in this area is still limited and largely focused on
patients with T2DM. Bisphosphonates, the most widely used
anti-osteoporotic therapy, have similar efficacy in individuals
with or without diabetes. Also there is evidence suggesting
that raloxifene has similar efficacy for prevention of vertebral
fractures in both individuals with or without T2DM [58]. In a
meta-analysis by Anagnostis et al., alendronate, raloxifene
and teriparatide demonstrated comparable vertebral anti-
fracture efficacy in individuals with or without diabetes [59].
Similarly, in the study by Langdahl et al., the authors aimed to
assess fracture outcomes in subgroups of osteoporosis patients
from four real-world teriparatide observational studies and
Fig. 2 This graph shows mortality risk in men (n = 4405) and women
(n = 15,417) with both vertebral fractures (VF) and type 2 diabetes
mellitus (T2DM) stratified by BMI categories (underweight (< 18.5 kg/
m2), normal weight (18.5–24.9 kg/m2), overweight (25.0–30.0 kg/m2)
and obese (> 30.0 kg/m2)). The data points represent hazard ratios (HR)
from Cox regression model adjusted for age (natural splines with 5 df),
corticosteroid use, anti-osteoporotic treatment and cohort. The figure
shows that obese men with T2DM with vertebral fractures have a
strikingly high mortality hazard ratio compared to either individuals
without T2DM or VF, with VF alone or with T2DM alone.
Figure adapted with permission [6]
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found that similarly to individuals without diabetes,
teriparatide also reduced clinical vertebral fracture risk in pa-
tients with T2DM [60]. A very recently published analysis of
FREEDOM and FREEDOM extension found that denosumab
in postmenopausal women with both osteoporosis and diabe-
tes significantly increased BMD and decreased vertebral frac-
ture risk [61].
A recent study using data from Medicare found that male
sex, history of cerebrovascular accident/stroke and history of
diabetes mellitus were risk factors associated with the lack of
prescription of anti-osteoporosis medication within 1 year af-
ter a vertebral compression fracture. Moreover they reported a
declining trend of anti-osteoporotic medication prescription
during a 6-year interval (2008–2015) [62]. There are currently
no guidelines on how to manage patients with T2DM who
might be at risk for osteoporotic fractures. In a recent review,
Ferrari et al. suggest to base the diagnosis of osteoporosis in
individuals with T2DM on presence of fragility fracture and/
or low BMD. They also recommend treatment thresholds to
be applied similarly in patients with T2DM to those applied to
the general population [63]. Furthermore, according to the
most recent UK guidelines for prevention and management
of osteoporosis, screening for vertebral fractures is recom-
mended in patients with T2DM deemed as at high risk to
acquire fractures such as postmenopausal women and older
men with a height loss above 4 cm, presence of kyphosis or
long-term use of glucocorticoids [64].
Future Directions
In addition to the mechanisms described above, more data is
needed on the complex pathophysiology that causes certain
patients with T2DM to fracture and to be predisposed to in-
creased mortality. Recently, the bone fragility in diabetes in
Europe-towards a personalized medicine approach
(FIDELIO) consortium has been founded. This research net-
work will be a basis for application of next-generation tech-
niques including investigations of the genetic epidemiological
aspects and biological pathways of diabetic bone disease
through Mendelian randomization. Other needs in the re-
search field are head-to-head studies comparing the different
anti-osteoporotic agents for their efficacy in preventing
(vertebral) fractures in T2DM patients.
Conclusions
Vertebral fracture risk is increased in individuals with T2DM.
Furthermore, vertebral fractures in individuals with T2DM seem
to be associated with increased mortality and non-vertebral frac-
ture risk compared with individuals with T2DM and without ver-
tebral fractures. Therefore, individuals with T2DM could benefit
from systematic screening in the clinic for the presence of vertebral
fractures. TBS seems to have utility in vertebral fracture risk as-
sessment in individuals with T2DM; estimating standardized clin-
ical threshold values for TBS could be of clinical value to improve
fracture risk assessment in individuals with T2DM. Bone marrow
fat assessment might also be useful for fracture risk assessment in
individuals with T2DM; therefore, clinical or epidemiological
studies are needed to estimate its utility. This might be difficult
in clinical practice due to the need of MRI. Results from two
recent studies show that both teriparatide and denosumab are ef-
fective in reducing vertebral fracture risk also in individuals with
T2DM. Efforts to prevent skeletal complications and decrease
their burden in patients with DM are needed.
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